Eton Pharmaceuticals: Growth Explosion in Rare Diseases – The Next Wave of Medications is Coming!

Eton achieves new patient records with its drugs for rare diseases. ASN-001 may expand the patient market by 2028. LIBERVANT is set to launch in 2027. After a 158% revenue increase and a 49% EBITDA margin, the annual forecast is rising. Eton Pharmaceuticals (ETON) acquires and develops medications for rare diseases and targets distribution through specialists. This allows for growth with a streamlined distribution model. In the third quarter, the main products reached patient records. This reflects organic progress; however, a significant...